Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 148-162 , April 2003

Imaging gliomas with positron emission tomography and single-photon emission computed tomography

References 

  1. American Cancer Society . Cancer Facts & Figures 2002. In: New York: American Cancer Society; 2002;p. 5
  2. Smirniotopoulos JG. The new WHO classification of brain tumors. Neuroimag Clin N Am. 1999;9:595–613
  3. Levin VA, Leibel SA, Gutin PH. Neoplasms of the Central Nervous System. In:  De Vita VT,  Hellman S,  Gutin PH editor. Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001; Cancer
  4. Vandenberg S, Sampaio Lopes MB. In:  Berger MS,  Wilson CB editor. Classification. The Gliomas Philadelphia: WB Saunders; 1999;p. 172–191
  5. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: A critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95:735–745
  6. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123
  7. Ricci PE. Imaging of adult brain tumors. Neuroimag Clin N Am. 1999;9:651–669
  8. Nelson SJ. Imaging of brain tumors after therapy. Neuroimag Clin N Am. 1999;9:801–819
  9. Ancri D, Basset JY, Lonchampt MF, et al.  Diagnosis of cerebral lesions by Thallium 201. Radiology. 1978;128:417–422
  10. Kaplan WD, Takvorian T, Morris JH, et al.  Thallium-201 brain tumor imaging: A comparative study with pathologic correlation. J Nucl Med. 1987;28:47–52
  11. Kim KT, Black KL, Marciano D, et al.  Thallium-201 SPECT imaging of brain tumors: Methods and results. J Nucl Med. 1990;31:965–969
  12. Oriuchi N, Tamura M, Shibazaki T, et al.  Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. J Nucl Med. 1993;34:2085–2089
  13. Jinnouchi S, Hoshi H, Ohnishi T, et al.  Thallium-201 SPECT for predicting histological types of meningiomas. J Nucl Med. 1993;34:2091–2094
  14. Ishibashi M, Taguchi A, Sugita Y, et al.  Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J Nucl Med. 1995;36:2201–2206
  15. Dierckx RA, Martin JJ, Dobbeleir A, et al.  Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumors. Eur J Nucl Med. 1994;21:621–633
  16. Ricci M, Pantano P, Pierallini A, et al.  Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging. Eur J Nucl Med. 1996;23:524–529
  17. Sun D, Liu Q, Liu W, et al.  Clinical application of 201T1 SPECT imaging of brain tumors. J Nucl Med. 2000;41:5–10
  18. Staffen W, Hondl N, Trinka E, et al.  Clinical relevance of 201T1-chloride SPET in the differential diagnosis of brain tumors. Nucl Med Commun. 1998;19:335–340
  19. O'Tuama LA, Treves ST, Larar JN, et al.  Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: A within-subject comparison. J Nucl Med. 1993;34:1045–1051
  20. Bagni B, Pinna L, Tamarozzi R, et al.  SPET imaging of intracranial tumors with 99Tcm-sestamibi. Nucl Med Commun. 1995;16:258–264
  21. Soler C, Beauchesne P, Maatougui K, et al.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med. 1998;25:1649–1657
  22. Yokogami K, Kawano H, Moriyama T, et al.  Application of SPET using technetium-99m sestamibi in brain tumors and comparison with expression of the MDR-1 gene: Is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?. Eur J Nucl Med. 1998;25:401–409
  23. Nishiyama Y, Yamamoto Y, Fukunaga K, et al.  Comparison of 99Tcm-MIBI with 201T1 chloride SPET in patients with malignant brain tumours. Nucl Med Commun. 2001;22:631–639
  24. Soricelli A, Cuocolo A, Varrone A, et al.  Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: Comparison with thallium-201 imaging. J Nucl Med. 1998;39:802–806
  25. Biersack HJ, Coenen HH, Stocklin G, et al.  Imaging of brain tumors with [I-123]iodo-alpha-methyl tyrosine and SPECT. J Nucl Med. 1989;30:110–112
  26. Langen KJ, Muhlensiepen H, Holschbach M, et al.  Transport mechanisms of [I-123]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl-L-methionine. J Nucl Med. 2000;41:1250–1255
  27. Kuwert T, Morgenroth C, Woesler B, et al.  Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med. 1996;23:1345–1353
  28. Kuwert T, Woesler B, Morgenroth C, et al.  Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. [erratum appears in J Nucl Med 1998 Mar;39(3):574.] J Nucl Med. 1998;39:23–27
  29. Schmidt D, Gottwald U, Langen KJ, et al.  [I-123]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med. 2001;28:855–861
  30. Weber WA, Dick S, Reidl G, et al.  Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med. 2001;42:1144–1150
  31. Langen KJ, Ziemons K, Kiwit JC, et al.  [123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997;38:517–522
  32. Weber W, Bartenstein P, Gross MW, et al.  Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med. 1997;38:802–880
  33. Woesler B, Kuwert T, Morgenroth C, et al.  Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med. 1997;24:428–434
  34. Bader JB, Samnick S, Moringlane JR, et al.  Evaluation of 1-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med. 1999;26:144–151
  35. Sasaki M, Kuwabara Y, Yoshida T, et al.  A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25:1261–1269
  36. Samnick S, Hellwig D, Bader JB, et al.  Initial evaluation of the feasibility of single photon emission tomography with p[I-123]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun. 2002;23:121–130
  37. Wrenn F, Good M, Handler P. The use of positron emitting radioisotopes for localization of brain tumors. Science. 1951;113:525–527
  38. Brownell G, Sweet W. Localization of brain tumors with positron emitters. Nucleonics. 1953;11:40–45
  39. Schelstraete K, Simons M, Deman J, et al.  Uptake of 13N-ammonia by human tumors as studied by positron emission tomography. Br J Radiol. 1982;55:797–804
  40. Ito M, Lammertsma A, Wise R, et al.  Measurement of regional cerebral blood flow and oxygen utilization in patients with cerebral tumors using 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology. 1982;23:63–67
  41. Leenders K. PET: Blood flow and oxygen consumption in brain tumors. J Neuro-Oncol. 1994;22:269–273
  42. Shields AF, Lim K, Grierson J, et al.  Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med. 1990;31:337–342
  43. Vander Borght T, Pauwels S, Lambotte L, et al.  Brain tumor imaging with PET and 2-[carbon-11]Thymidine. J Nucl Med. 1994;25:974–982
  44. De Reuck J, Santens P, Goethals P, et al.  [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg. 1999;99:118–125
  45. Eary JF, Mankoff DA, Spence AM, et al.  2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615–621
  46. Blasberg RG, Roelcke U, Weinreich R, et al.  Imaging brain tumor proliferative activity with [I-124]iododeoxyuridine. Cancer Res. 2000;60:624–635
  47. Shields AF, Grierson JR, Dohmen BM, et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  48. Warnick RE, Pietronigro DD, McBride DQ, et al.  In vivo metabolism of radiolabeled putrescine in gliomas: implications for positron emission tomography of brain tumors. Neurosurgery. 1988;23:464–469
  49. Mitsuki S, Diksic M, Conway T, et al.  Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol. 1991;10:47–55
  50. Valk P, Mathis C, Prados M, et al.  Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–2137
  51. Fulham MJ, Bizzi A, Dietz MJ, et al.  Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 1992;185:675–686
  52. Shinoura N, Nishijima M, Hara T, et al.  Brain tumors: detection with C-11 choline PET. Radiology. 1997;202:497–503
  53. Ohtani T, Kurihara H, Ishiuchi S, et al.  Brain tumour imaging with carbon-11 choline: Comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001;28:1664–1670
  54. DeGrado TR, Baldwin SW, Wang S, et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  55. Kubota K, Yamada K, Fukada H, et al.  Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med. 1984;9:136–140
  56. Ishiwata K, Kubota K, Murakami M, et al.  Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo?. J Nucl Med. 1993;34:1936–1943
  57. Lilja A, Bergstrom K, Hartvig P, et al.  Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. AJNR Am J Neuroradiol. 1985;6:505–514
  58. Bustany P, Chatel M, Derlon JM, et al.  Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine. J Neurooncol. 1986;3:397–404
  59. Derlon JM, Bourdet C, Bustany P, et al.  [11C]L-methionine uptake in gliomas. Neurosurgery. 1989;25:720–728
  60. Kameyama M, Shirane R, Itoh J, et al.  The accumulation of 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien). 1990;104:8–12
  61. Vaalburg W, Coenen HH, Crouzel C, et al.  Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B. 1992;19:227–237
  62. Ishiwata K, Kubota K, Murakami M, et al.  A comparative study on protein incorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol. 1993;20:895–899
  63. Kubota K, Kubota R, Yamada S, et al.  Effects of radiotherapy on the cellular uptake of carbon-14 labeled L-methionine in tumor tissue. Nucl Med Biol. 1995;22:193–198
  64. Kubota K, Ishiwata K, Kubota R, et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine and gallium-67. J Nucl Med. 1991;32:2118–2123
  65. Derlon JM, Petit-Taboue MC, Chapon F, et al.  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery. 1997;40:276–287 discussion 287-288
  66. Kaschten B, Stevenaert A, Sadzot B, et al.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  67. Bergstrom M, Collins VP, Ehrin E, et al.  Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr. 1983;7:1062–1066
  68. Ogawa T, Kanno I, Shishido F, et al.  Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 1991;32:197–202
  69. Pirotte B, Goldman S, Bidaut LM, et al.  Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien). 1995;134:79–82
  70. Roelcke U, Radu EW, von Ammon K, et al.  Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci. 1995;132:20–27
  71. Ogawa T, Shishido F, Kanno I, et al.  Cerebral glioma: evaluation with methionine PET. Radiology. 1993;186:45–53
  72. Voges J, Herholz K, Holzer T, et al.  11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotactic Functional Neurosurg. 1997;69:129–135
  73. De Witte O, Goldberg I, Wikler D, et al.  Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746–750
  74. Herholz K, Holzer T, Bauer B, et al.  11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–1322
  75. Lemaire C, Damhaut P, Lauricella B, et al.  Fast [18F]FDG synthesis by alkaline hydrolysis on a low polarity solid phase support. J Labelled Cpd Radiopharm. 2002;45:435–447
  76. Wienhard K, Herholz K, Coenen HH, et al.  Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med. 1991;32:1338–1346
  77. Warburg O. The Metabolism of Tumors. London: Constable and Company Limited; 1930;
  78. Weber G. Enzymology of cancer cells. N Engl J Med. 1977;296:486–493 541-551
  79. Hatanaka M, Augl C, Gilden RV. Evidence for a functional change in the plasma membrane of murine sarcoma virus-infected mouse embryo cells. Transport and transport-associated phosphorylation of 14C-2-deoxy-D-glucose. J Biol Chem. 1970;245:714–717
  80. Gallagher B, Fowler J, Gutterson N, et al.  Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F]deoxyglucose. J Nucl Med. 1989;19:1154–1161
  81. Merrall N, Plevin R, Gould G. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal. 1993;5:667–675
  82. Nishioka T, Oda Y, Seino Y, et al.  Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52:3972–3979
  83. Herholz K, Pietrzyk U, Voges J, et al.  Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg. 1993;79:853–858
  84. Patronas NJ, Di Chiro G, Brooks RA, et al.  Work in progress: [18F] Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885–889
  85. Di Chiro G, DeLaPaz RL, Brooks RA, et al.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323–1329
  86. Kim CK, Alavi JB, Alavi A, et al.  New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol. 1991;10:85–91
  87. Meyer PT, Schreckenberger M, Spetzger U, et al.  Comparison of visual and ROI-based brain tumor grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165–174
  88. Hustinx R, Smith RJ, Benard F, et al.  Can the standardized uptake value characterize primary brain tumors on FDG-PET?. Eur J Nucl Med. 1999;26:1501–1509
  89. Hoffman JM, Hanson MW, Friedman HS, et al.  FDG-PET in pediatric posterior fossa brain tumors. J Comput Assist Tomogr. 1992;16:62–68
  90. Holthoff VA, Herholz K, Berthold F, et al.  In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 1993;72:1394–1403
  91. Patronas NJ, Brooks RA, DeLaPaz RL, et al.  Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol. 1983;4:533–535
  92. Alavi JB, Alavi A, Chawluk J, et al.  Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988;62:1074–1078
  93. Holzer T, Herholz K, Jeske J, et al.  FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr. 1993;17:681–687
  94. De Witte f, Lefranc F, Levivier M, et al.  FDG-PET as a prognostic factor in high-grade astrocytoma. J Neuro-Oncol. 2000;49:157–163
  95. Di Chiro G, Oldfield E, Wright DC, et al.  Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189–197
  96. Glantz MJ, Hoffman JM, Coleman RE, et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991;29:347–355
  97. Buchpiguel CA, Alavi JB, Alavi A, et al.  PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med. 1995;36:159–164
  98. Kim EE, Chung SK, Haynie TP, et al.  Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics. 1992;12:269–279
  99. Brock CS, Young H, O'Reilly SM, et al.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer. 2000;82:608–615
  100. Rozental JM, Levine RL, Nickles RJ, et al.  Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol. 1989;46:1302–1307
  101. Rozental JM, Levine RL, Mehta MP, et al.  Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1991;20:1053–1060
  102. Francavilla T, Miletich R, Di Chiro G, et al.  Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery. 1989;24:1–5
  103. De Witte O, Levivier M, Violon P, et al.  Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery. 1996;39:470–476 discussion 476-477
  104. Hanson MW, Glantz MJ, Hoffman JM, et al.  FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr. 1991;15:796–801
  105. Di Chiro G, Brooks RA, Patronas NJ, et al.  Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol. 1984;15(supp):S138–S146
  106. Jacobs A, Dubrovin M, Hewett J, et al.  Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: Implications for noninvasive imaging of transgene expression. Neoplasia. 1999;1:154–161
  107. Jacobs A, Tjuvajev JG, Dubrovin M, et al.  Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001;61:2983–2995
  108. Tjuvajev JG, Doubrovin M, Akhurst T, et al.  Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002;43:1072–1083

☆ Address reprint requests to Roland Hustinx, Division of Nuclear Medicine, Centre Hosptalier Universitaire, Sart Tilman B35, 4000 LIEGE1, Belgium.

☆☆ 0001-2998/03/3302-0001$30.00/0

PII: S0001-2998(03)70019-1

doi: 10.1053/snuc.2003.127304

Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 148-162 , April 2003

Article Tools

* Image Usage & Resolution